Rein Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Rein Therapeutics, Inc. (RNTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $164.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $164.00K, a 35.94% decline year-over-year.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $156.00K, a 40.91% decline year-over-year.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.45M, a 184.84% increase year-over-year.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $256.00K, a 21.47% decline year-over-year.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.22M, a 99.10% increase from fiscal 2024.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.12M, a 6.13% decline from fiscal 2023.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.19M, a 42.87% decline from fiscal 2022.
- Rein Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.08M, a 7.83% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $164.00K 10-Q · filed 2026-08-14 | $320.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $156.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $2.22M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $1.45M 10-Q · filed 2025-11-14 | $1.70M derived: sum of 2 quarters · filed 2026-08-14 | $1.97M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $256.00K 10-Q · filed 2026-08-14 | $520.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $264.00K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $1.12M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $508.00K 10-Q · filed 2025-11-14 | $834.00K derived: sum of 2 quarters · filed 2025-11-14 | $984.00K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $326.00K 10-Q · filed 2025-11-14 | $476.00K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $150.00K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $1.19M 10-K · filed 2025-04-07 | |||
| 2023-09-30 | $229.00K 10-Q · filed 2024-11-14 | $529.00K derived: sum of 2 quarters · filed 2024-11-14 | $920.00K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $300.00K 10-Q · filed 2024-11-14 | $691.00K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $391.00K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $2.08M 10-K · filed 2024-04-15 | |||
| 2022-09-30 | $442.00K 10-Q · filed 2023-10-13 | $970.00K derived: sum of 2 quarters · filed 2023-10-13 | $1.66M derived: sum of 3 quarters · filed 2023-10-13 | |
| 2022-06-30 | $528.00K 10-Q · filed 2023-10-13 | $1.22M derived: sum of 2 quarters · filed 2023-10-13 | ||
| 2022-03-31 | $689.00K 10-Q · filed 2023-10-13 | |||
| 2021-12-31 | $2.26M 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $661.00K 10-Q · filed 2022-11-01 | $1.02M derived: sum of 2 quarters · filed 2022-11-01 | $1.65M derived: sum of 3 quarters · filed 2022-11-01 | |
| 2021-06-30 | $361.00K 10-Q · filed 2022-11-01 | $992.00K derived: sum of 2 quarters · filed 2022-11-01 | ||
| 2021-03-31 | $631.00K 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | $1.89M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $465.00K 10-Q · filed 2021-11-12 | $1.02M derived: sum of 2 quarters · filed 2021-11-12 | $1.53M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $560.00K 10-Q · filed 2021-11-12 | $1.06M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $505.00K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $2.12M 10-K · filed 2021-03-24 | |||
| 2019-09-30 | $614.00K 10-Q · filed 2020-11-12 | $1.07M derived: sum of 2 quarters · filed 2020-11-12 | $1.64M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $460.00K 10-Q · filed 2020-11-12 | $1.02M derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $563.00K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $3.28M 10-K · filed 2020-03-30 | |||
| 2018-09-30 | $588.00K 10-Q · filed 2019-11-07 | $1.92M derived: sum of 2 quarters · filed 2019-11-07 | $2.69M derived: sum of 3 quarters · filed 2019-11-07 | $3.35M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $1.33M 10-Q · filed 2019-11-07 | $2.10M derived: sum of 2 quarters · filed 2019-11-07 | $2.77M derived: sum of 3 quarters · filed 2019-11-07 | $3.38M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-03-31 | $767.00K 10-Q · filed 2019-11-07 | $1.43M derived: sum of 2 quarters · filed 2019-11-07 | $2.05M derived: sum of 3 quarters · filed 2019-11-07 | |
| 2017-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $1.28M derived: sum of 2 quarters · filed 2019-03-29 | $1.75M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $615.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.08M 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $469.00K 10-Q · filed 2017-08-10 | |||
| 2016-12-31 | $688.00K 10-K · filed 2018-04-02 | |||
| 2015-12-31 | $626.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |